Voltage-gated calcium channel protein alpha-1 subunit (CaVα1)

The voltage-gated calcium channel protein alpha-1 subunit (CaVα1) is the main pore-forming and voltage-sensing component of the voltage-gated calcium channel complex. It consists of four homologous domains (I–IV), each containing six transmembrane segments, which together form a central pore selective for calcium ions. The alpha-1 subunit is responsible for channel gating, ion selectivity, and is the primary drug/toxin target site[1][2][3][4]. Different gene isoforms give rise to functionally distinct channel types (e.g., L-type, N-type, P/Q-type, R-type, T-type) that play essential roles in excitable tissues such as muscle, heart, and neurons. This protein is associated with various physiological processes, including muscle contraction, synaptic transmission, and hormone secretion, and is a major target for several classes of therapeutic drugs and toxins[1][4][5][7]. Dysregulation or mutation can lead to a wide range of diseases, making it a key focus in the development of therapies for cardiovascular, neurological, and muscular disorders.

Other names

CaVα1Calcium channel alpha-1 subunitVarious gene-based aliases such as CACNA1S (skeletal muscle)CACNA1C (cardiac/neuronal L-type)CACNA1ECACNA1Aetc., according to subtype

Direct blockade of the channel pore (prevents calcium ion entry) Allosteric modulation (modifies channel gating or kinetics) Auxiliary subunit displacement/modulation (alters trafficking and current amplitude) Inhibition of neurotransmitter/hormone secretion (secondary to calcium entry blockade)